Access cutting-edge non-hodgkin lymphoma treatment through this clinical trial at a research site in Indianapolis. Study-provided care at no cost to qualified participants.
Access non-hodgkin lymphoma specialists in Indianapolis at no cost
This study follows strict safety protocols and ethical guidelines
All study-related non-hodgkin lymphoma treatment provided free
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.
Sponsor: Lyell Immunopharma, Inc.
Check if you qualify for this non-hodgkin lymphoma clinical trial in Indianapolis, IN
If you're searching for non-hodgkin lymphoma treatment options in Indianapolis, IN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Indianapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced non-hodgkin lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.